Todd A. Fehniger, MD, PhD – New Medical and Scientific Director of the BTCF
March 13, 2018
I am very pleased to announce Todd A. Fehniger, MD, PhD, as the new Medical and Scientific Director of the Biologic Therapy Core Facility (BTCF).
Dr. Fehniger is an Associate Professor of Medicine in the Division of Oncology and Section of Bone Marrow Transplantation and Leukemia at Siteman Cancer Center. Fehniger received his MD and PhD degrees from The Ohio State University and completed an internal medicine residency at Barnes-Jewish Hospital.
After completing a hematology and oncology fellowship at Washington University, he continued his clinical and research career as a faculty member in the Department of Medicine’s oncology division. His clinical interests include the treatment of lymphoma and leukemia as well as immunotherapy and hematopoietic cell transplantation. His basic and translational research program studies innate immunity, cytokines, and natural killer cell biology and their therapeutic uses. Fehniger holds numerous peer-reviewed funding awards, serves as the site co-PI for the Clinical Immunotherapy Trials Network, and scientific co-director of the Center for Gene and Cellular Immunotherapy.
In his role as the Medical and Scientific Director of the BTCF, Fehniger will provide vision, leadership, medical oversight, and scientific guidance of drug product development and cellular therapy in the BTCF.
Executive Director of Research & Business Administration
Siteman Cancer Center
Washington University & Barnes Jewish Hospital